Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.
Skalniak, L., Zak, K.M., Guzik, K., Magiera, K., Musielak, B., Pachota, M., Szelazek, B., Kocik, J., Grudnik, P., Tomala, M., Krzanik, S., Pyrc, K., Domling, A., Dubin, G., Holak, T.A.(2017) Oncotarget 8: 72167-72181
- PubMed: 29069777 
- DOI: 10.18632/oncotarget.20050
- Primary Citation of Related Structures:  
5NIU - PubMed Abstract: 
Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years. In contrast, no small molecules with cellular activity have been reported so far. Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes ...